BioArctic AB Registered b Aktie [WKN DE: A2H5GS / ISIN: SE0010323311]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BioArctic AB Registered Shs -B-

09.11.20		Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020 (PR Newswire)
09.11.20		Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020 (PR Newswire)
28.10.20		BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference (PR Newswire)
28.10.20		BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference (PR Newswire)
15.10.20		BioArctic winner of the Allbright Award 2020 (PR Newswire)
15.10.20		BioArctic winner of the Allbright Award 2020 (PR Newswire)
06.10.20		Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET (PR Newswire)
06.10.20		Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET (PR Newswire)
30.07.20		Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020 (PR Newswire)
30.07.20		Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020 (PR Newswire)
22.07.20		BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020 (PR Newswire)
22.07.20		BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020 (PR Newswire)
14.07.20		New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease (PR Newswire)
14.07.20		New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease (PR Newswire)
01.07.20		Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET (PR Newswire)
01.07.20		Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET (PR Newswire)
29.06.20		BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease (PR Newswire)
29.06.20		BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease (PR Newswire)
26.05.20		Members of BioArctic's Board of Directors and Management Increase Their Shareholdings (PR Newswire)
26.05.20		Members of BioArctic's Board of Directors and Management Increase Their Shareholdings (PR Newswire)
07.05.20		Report from Annual General Meeting in BioArctic (publ) (PR Newswire)
07.05.20		Report from Annual General Meeting in BioArctic (publ) (PR Newswire)
22.04.20		Interim Report for the period January - March 2020 (PR Newswire)
22.04.20		Interim Report for the period January - March 2020 (PR Newswire)
15.04.20		Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET (PR Newswire)
15.04.20		Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET (PR Newswire)
03.03.20		Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401 (PR Newswire)
03.03.20		Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401 (PR Newswire)
17.12.19		BioArctic Announces Research Collaboration with Eisai Regarding BAN2401 (PR Newswire)
17.12.19		BioArctic Announces Research Collaboration with Eisai Regarding BAN2401 (PR Newswire)
10.12.19		BioArctic Strengthens its Management Team With Two Strategic Recruitments (PR Newswire)
05.12.19		BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease (PR Newswire)
05.12.19		BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease (PR Newswire)
02.12.19		BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference (PR Newswire)
02.12.19		BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference (PR Newswire)
19.11.19		BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury (PR Newswire)
19.11.19		BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury (PR Newswire)
18.07.19		BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
18.07.19		BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
15.07.19		BioArctic's Co-Founder Received AAIC Lifetime Achievement Award (PR Newswire)
15.07.19		BioArctic's Co-Founder Received AAIC Lifetime Achievement Award (PR Newswire)
11.07.19		BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
11.07.19		BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
23.05.19		BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment (PR Newswire)
20.05.19		BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease (PR Newswire)
20.05.19		BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease (PR Newswire)
10.05.19		BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease (PR Newswire)
10.05.19		BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease (PR Newswire)
03.04.19		BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies (PR Newswire)
03.04.19		BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.11.2024 23:36
Kaufwert:	EUR
	Hinzufügen Speichern